Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Arsenic trioxide
Drug ID BADD_D00169
Description Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Indications and Usage For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Marketing Status approved; investigational
ATC Code L01XX27
DrugBank ID DB01169
KEGG ID D02106
MeSH ID D000077237
PubChem ID 14888
TTD Drug ID D07VIK
NDC Product Code 64743-400; 14789-600; 49315-007; 54973-0605; 68428-033; 70710-1610; 43406-0168; 49315-005; 68083-462; 68428-225; 64757-0001; 23155-870; 0220-0522; 0220-0527; 0220-0549; 70710-1896; 55150-366; 25021-226; 43406-0318; 0220-0554; 0220-0557; 63323-637; 81607-005; 64757-0016; 0220-0528; 54879-027; 62106-4878; 58621-001; 0220-0530; 68428-083; 70710-1895; 0220-0553; 63459-601; 69918-720; 70121-1483; 76472-3004; 81607-006; 72659-245; 0220-0526; 50742-438; 68083-535; 0781-3498; 54875-0005; 23155-869; 25021-227; 0220-0525; 0220-0550; 68382-997; 70121-1658; 70860-217; 76472-1132; 76472-4004; 0220-0529
UNII S7V92P67HO
Synonyms Arsenic Trioxide | As2O3 | Arsenous Anhydride | Diarsenic Trioxide | Arsenic Oxide (As2O3) | Arsenic(III) Oxide | Tetraarsenic Oxide | Arsenolite | As4O6 | Tetra-Arsenic Oxide | Tetra Arsenic Oxide | Tetraarsenic Hexaoxide | Arsenic Oxide (As4O6) | Tetra-Arsenic Hexaoxide | Tetra Arsenic Hexaoxide | Naonobin | Trisenox | Trixenox
Chemical Information
Molecular Formula As2O3
CAS Registry Number 1327-53-3
SMILES [O-2].[O-2].[O-2].[As+3].[As+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.004--Not Available
Acidosis14.01.03.002--
Acute hepatic failure09.01.03.0010.000112%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.000112%Not Available
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Anxiety19.06.02.002--
Arrhythmia supraventricular02.03.03.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.0020.000112%
Atrial flutter02.03.03.003--
Atrioventricular block02.03.01.0020.000336%Not Available
Atrioventricular block second degree02.03.01.0050.000112%
Back pain15.03.04.005--
Blister12.01.06.002; 23.03.01.001--Not Available
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.0010.000112%
Cardiac failure02.05.01.0010.000168%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000112%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000168%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene